Finding MYCure

Marie Eve Beaulieu, Laura Soucek

Research output: Contribution to journalArticleResearch

Abstract

© 2019, © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
Original languageEnglish
Article numbere1618178
JournalMolecular and Cellular Oncology
Volume6
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • mini-protein
  • MYC
  • NSCLC
  • OMOMYC
  • peptide therapeutic

Fingerprint Dive into the research topics of 'Finding MYCure'. Together they form a unique fingerprint.

Cite this